Regulatory filing 📈 Stocks 🌍 United States

Rani Therapeutics Transfers to Nasdaq Capital Market, Gains 180-Day Extension

Rani Therapeutics secures a listing transfer to the Nasdaq Capital Market, providing a new May 10, 2027 deadline to resolve its minimum bid price deficiency and avoid potential delisting.

📅 November 12, 2026 🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: RANI ↑ 4/10 (65% confidence).

📊 Affected Assets (1)

RANI

Bullish 🤖 65%

📅 Short-term 🌍 US · Explicit

On November 10, 2026, Nasdaq approved the transfer of RANI's listing to the Nasdaq Capital Market and granted a new 180-day deadline, until May 10, 2027, to regain the $1.00 minimum bid price. This removes the immediate delisting risk that was set to trigger on November 9, 2026, which offers relief. However, the stock remains below $1.00 and the company may need a reverse stock split, leaving compliance risk unresolved.

Catalysts

▲ Nasdaq approval of transfer to Nasdaq Capital Market effective at the opening of business on November 12, 2026
▲ New 180-day compliance deadline of May 10, 2027 to regain the $1.00 minimum bid price

Risk Factors

▼ No assurance the company will regain compliance; continued trading below $1.00
▼ Potential reverse stock split could be needed

🧭 Full analysis of these assets

🎯 Key Takeaways

Nasdaq approved the transfer of RANI to the Nasdaq Capital Market effective November 12, 2026.
The company received a new 180-day compliance period ending May 10, 2027, to reach the $1.00 minimum bid price.
Rani Therapeutics signaled it may implement a reverse stock split to regain compliance with Nasdaq Listing Rule 5450(a)(1).
To regain compliance, the stock must maintain a closing bid price of at least $1.00 for at least 10 consecutive business days.

📝 Executive Summary

Rani Therapeutics Holdings has successfully transferred its Class A common stock listing to the Nasdaq Capital Market effective November 12, 2026. This move grants the company an additional 180-day period, extending the deadline to May 10, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company has indicated it may pursue a reverse stock split if necessary to meet listing standards.

❓ FAQ

What happens if RANI does not reach $1.00 per share?

The 8-K states there can be no assurance of regaining compliance; the company could face delisting if it fails to meet the $1.00 minimum bid price requirement by May 10, 2027, and it may use a reverse stock split to try to cure the deficiency.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article